Global Bio-chem Technology Group Co. Ltd. (0809) AI Stock Analysis

• Market Cap: HK$1.36B
• Dividend Yield: N/A
• Average Volume (3M): 10.78M
• Price to Earnings (P/E): 0.9
• Beta (1Y): -0.23
• Revenue Growth: 42.14%
• EPS Growth: -81.25%
• Country: HK
• Employees: 1,567
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 16,832,771,000
• 10 Day Avg. Volume: 19,128,200
• 30 Day Avg. Volume: 10,781,266
• PEG Ratio: -0.02
• Price to Book (P/B): -0.48
• Price to Sales (P/S): 0.47
• P/FCF Ratio: 12.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's poor financial performance, characterized by negative equity and high leverage. Technical analysis indicates bearish momentum, further weighing down the score. While the valuation suggests potential undervaluation, the financial instability and technical indicators present significant risks.

Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model

Company Description

Global Bio-chem Technology Group Co. Ltd. (0809) is a leading biotechnology company specializing in the production of bio-based products and chemicals. The company primarily operates in the bio-chemicals sector, focusing on the development and manufacturing of biodegradable materials, biofuels, and other bio-based chemicals. Its core products include bio-monomers, bio-plastics, and various bio-chemicals that serve multiple industries, including packaging, automotive, and consumer goods, contributing to a more sustainable future.

How the Company Makes Money

Global Bio-chem Technology Group Co. Ltd. generates revenue through the sale of its bio-based products and chemicals to various industrial sectors. The company has established a diversified revenue model that includes direct sales of its core products, long-term contracts with key customers, and partnerships with other firms in the bio-chemicals and materials industry. Significant revenue streams come from bulk sales of biodegradable plastics and chemicals, which have seen increasing demand due to the global shift towards sustainability. Additionally, collaborations with research institutions and participation in government initiatives for green technology further enhance its revenue potential.

Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview

Summary

The company exhibits major financial instability with negative equity, high leverage, and inconsistent cash flows. Despite recent improvements in revenue and operating cash flow, the company remains at risk due to historical losses and financial distress.

Income Statement

The company shows significant volatility in revenue, with a recent increase from 2022 to 2023, but overall negative EBIT and net income suggest underlying profitability issues. The negative EBIT margin underscores operational challenges, while EBITDA margin turning positive in 2024 reflects some improvement in operating efficiency.

Balance Sheet

The company faces severe financial instability with negative stockholders' equity reflecting balance sheet insolvency, and a high debt-to-equity ratio indicating excessive leverage. The negative equity ratio further highlights financial distress, posing considerable risks.

Cash Flow

Cash flow from operations has improved from negative to positive in 2024, indicating better cash management. However, the free cash flow still faces challenges due to historical negative trends, and the operating cash flow to net income ratio is volatile, highlighting cash flow unpredictability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.29B	2.00B	1.37B	12.71M	746.55M	848.87M
Gross Profit	313.85M	218.68M	43.64M	-263.37M	48.35M	74.10M
EBITDA	104.98M	16.85M	4.69B	-469.06M	785.63M	-1.39B
Net Income	772.61M	769.60M	4.22B	-1.44B	-400.80M	-2.43B
Balance Sheet
Total Assets	4.69B	4.54B	5.21B	5.85B	6.48B	7.60B
Cash, Cash Equivalents and Short-Term Investments	221.55M	85.47M	315.41M	41.77M	109.13M	153.32M
Total Debt	3.60B	3.69B	5.45B	8.91B	8.44B	8.96B
Total Liabilities	6.89B	6.50B	9.25B	13.64B	13.18B	13.62B
Stockholders Equity	-2.21B	-1.95B	-4.04B	-7.54B	-6.52B	-5.86B
Cash Flow
Free Cash Flow	64.48M	76.04M	-94.24M	-94.19M	-501.02M	-43.02M
Operating Cash Flow	67.68M	76.04M	-50.46M	-88.01M	-475.21M	-26.19M
Investing Cash Flow	-3.74M	-535.00K	-14.37M	-413.00K	392.59M	120.09M
Financing Cash Flow	29.89M	-76.06M	112.62M	109.75M	-48.66M	-25.87M

Global Bio-chem Technology Group Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 28.40 is Positive, neither overbought nor oversold. The STOCH value of 16.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0809.

Global Bio-chem Technology Group Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2317	72 Outperform	HK$1.02B	8.55	5.08%	10.12%	-1.19%	-9.05%
1767	68 Neutral	HK$280.00M	10.61	5.48%	0.82%	5.43%	-25.42%
3838	65 Neutral	HK$1.16B	2.57	10.38%	5.10%	-6.58%	16.23%
0829	64 Neutral	HK$872.23M	-36.99	-0.99%	14.55%	-4.42%	-157.03%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2147	56 Neutral	HK$59.36M	-0.45	-28.48%	―	56.39%	-81.41%
0809	44 Neutral	HK$1.36B	0.94	―	―	42.14%	-81.25%

Global Bio-chem Technology Group Co. Ltd. Corporate Events

Global Bio-chem Completes Share Issuance and Bond Conversion to Restructure Debt

Global Bio-chem Technology Group Co. Ltd. has successfully completed the issuance of Consideration Shares under a specific mandate and the conversion of Convertible Bonds. This strategic move, which involved the issuance of over 2.7 billion Consideration Shares and the conversion of bonds into over 5.1 billion shares, allows the company to fully capitalize its Suppliers Debt, making the Target Companies its wholly-owned subsidiaries. This restructuring is expected to enhance the company’s financial stability and operational efficiency.

Global Bio-chem Technology Group Co. Ltd. EGM Resolution Passed

Global Bio-chem Technology Group Co. Ltd. announced that an ordinary resolution was passed at their Extraordinary General Meeting (EGM), approving the Share Purchase Agreements (SPAs) and related transactions. The resolution included granting a Specific Mandate for the allotment and issuance of Consideration Shares, with unanimous support from shareholders. This decision reflects the company’s strategic direction and could potentially enhance its market position by facilitating new transactions and expansions.

Global Bio-chem Technology Reports Increased Revenue but Sustains Losses in H1 2025

Global Bio-chem Technology Group Co. Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a revenue increase to HK$1,185,983,000 from HK$898,541,000 in the same period of 2024. Despite the revenue growth, the company faced a total comprehensive loss of HK$251,895,000, attributed to high finance costs and other expenses, impacting its financial performance and indicating challenges in maintaining profitability.

Global Bio-chem Announces Extraordinary General Meeting for Strategic Approvals

Global Bio-chem Technology Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for September 18, 2025, in Hong Kong. The meeting aims to approve resolutions related to the company’s strategic plans, including the allotment and issuance of Consideration Shares under Specific Mandates. This move is expected to impact the company’s operational strategies and potentially influence its market positioning.

Global Bio-chem Announces Delay in Debt Restructuring Circular

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The circular, initially expected by 22 August 2025, will now be dispatched by 5 September 2025, as additional time is needed to finalize certain information. This delay may impact stakeholders awaiting detailed information on the debt restructuring and share issuance.

Global Bio-chem Technology Schedules Board Meeting for Interim Results

Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.

Global Bio-chem Secures EPC Contract for Boiler Refurbishment

Global Bio-chem Technology Group Co. Ltd. announced the successful closure of a public tender for an EPC Contract related to a Boiler Refurbishment Project. The contract, valued at a maximum of RMB129.1 million, was awarded to Northeast Electric and Liaoning Electric as joint bidders. This transaction is classified as a discloseable transaction under the Listing Rules due to its size, requiring notification and announcement. The project involves comprehensive engineering, procurement, and construction tasks, with incentives for early completion, potentially impacting the company’s operational efficiency and market positioning.

Global Bio-chem Technology Delays Circular Dispatch for Debt Restructuring

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The delay is due to the need for additional time to prepare and finalize necessary information, with the new dispatch date set on or before August 22, 2025. This delay may impact the company’s operational timelines and stakeholder expectations, as the circular is crucial for informing shareholders about the upcoming Extraordinary General Meeting and related transactions.